BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28982740)

  • 1. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
    Sandborn WJ; Lee SD; Tarabar D; Louis E; Klopocka M; Klaus J; Reinisch W; Hébuterne X; Park DI; Schreiber S; Nayak S; Ahmad A; Banerjee A; Brown LS; Cataldi F; Gorelick KJ; Cheng JB; Hassan-Zahraee M; Clare R; D'Haens GR
    Gut; 2018 Oct; 67(10):1824-1835. PubMed ID: 28982740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's Disease.
    Hassan-Zahraee M; Banerjee A; Cheng JB; Zhang W; Ahmad A; Page K; von Schack D; Zhang B; Martin SW; Nayak S; Reddy P; Xi L; Neubert H; Fernandez Ocana M; Gorelick K; Clare R; Vincent M; Cataldi F; Hung K
    J Crohns Colitis; 2018 Jan; 12(1):77-86. PubMed ID: 28961803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study.
    Saruta M; Park DI; Kim YH; Yang SK; Jang BI; Cheon JH; Im JP; Kanai T; Katsuno T; Ishiguro Y; Nagaoka M; Isogawa N; Li Y; Banerjee A; Ahmad A; Hassan-Zahraee M; Clare R; Gorelick KJ; Cataldi F; Watanabe M; Hibi T
    Intest Res; 2020 Jan; 18(1):45-55. PubMed ID: 32013314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
    Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).
    Danese S; Vermeire S; Hellstern P; Panaccione R; Rogler G; Fraser G; Kohn A; Desreumaux P; Leong RW; Comer GM; Cataldi F; Banerjee A; Maguire MK; Li C; Rath N; Beebe J; Schreiber S
    Gut; 2019 Jan; 68(1):40-48. PubMed ID: 29247068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.
    Allocca M; Gilardi D; Fiorino G; Furfaro F; Argollo M; Peyrin-Biroulet L; Danese S
    Expert Opin Investig Drugs; 2018 Jul; 27(7):623-629. PubMed ID: 29985060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses.
    Watanabe K; Motoya S; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T
    J Gastroenterol; 2020 Mar; 55(3):291-306. PubMed ID: 31836930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.
    D'Haens G; Vermeire S; Vogelsang H; Allez M; Desreumaux P; Van Gossum A; Sandborn WJ; Baumgart DC; Ransohoff RM; Comer GM; Ahmad A; Cataldi F; Cheng J; Clare R; Gorelick KJ; Kaminski A; Pradhan V; Rivers S; Sikpi MO; Zhang Y; Hassan-Zahraee M; Reinisch W; Stuve O
    J Crohns Colitis; 2018 Jan; 12(2):188-196. PubMed ID: 28961770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), in Patients With Ulcerative Colitis or Crohn's Disease.
    Wang Y; Marier JF; Lavigne J; Kassir N; Martin P
    J Clin Pharmacol; 2020 Jul; 60(7):903-914. PubMed ID: 32119128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
    Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
    Dotan I; Rachmilewitz D; Schreiber S; Eliakim R; van der Woude CJ; Kornbluth A; Buchman AL; Bar-Meir S; Bokemeyer B; Goldin E; Maaser C; Mahadevan U; Seidler U; Hoffman JC; Homoky D; Plasse T; Powers B; Rutgeerts P; Hommes D;
    Gut; 2010 Jun; 59(6):760-6. PubMed ID: 20551461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.
    Sandborn WJ; Rutgeerts P; Colombel JF; Ghosh S; Petryka R; Sands BE; Mitra P; Luo A
    J Crohns Colitis; 2017 Jul; 11(7):811-819. PubMed ID: 28333187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
    Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T
    Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
    Sandborn WJ; Feagan BG; Loftus EV; Peyrin-Biroulet L; Van Assche G; D'Haens G; Schreiber S; Colombel JF; Lewis JD; Ghosh S; Armuzzi A; Scherl E; Herfarth H; Vitale L; Mohamed MF; Othman AA; Zhou Q; Huang B; Thakkar RB; Pangan AL; Lacerda AP; Panes J
    Gastroenterology; 2020 Jun; 158(8):2123-2138.e8. PubMed ID: 32044319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
    Vermeire S; D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Bhatia S; Agboton C; Rosario M; Chen C; Zhang W; Kisfalvi K; Sandborn WJ
    J Crohns Colitis; 2022 Jan; 16(1):27-38. PubMed ID: 34402887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.